The Sanford Project to Present Results of DiaMedica's DM-199 for Type 1 Diabetes at the IDF World Diabetes Congress Conference
September 27 2011 - 10:56AM
Marketwired
DiaMedica (TSX VENTURE: DMA) today announces that Dr. Alexi Savinov
of The Sanford Project has been invited to present a poster based
on its late-breaking abstract, detailing results of pre-clinical
studies of DM-199 for the treatment of Type 1 diabetes. The
material will be presented December 4-9, 2011 at the 21st biennial
World Diabetes Congress organized by the International Diabetes
Federation (IDF) in Dubai, United Arab Emirates.
The poster is entitled "Novel DM-199 compound provides potent
protection against diabetes development in non-obese diabetic (NOD)
mouse model by modulating autoimmunity."
The Sanford Project and DiaMedica previously announced
high-level results that DM-199 administration to NOD mice, the gold
standard animal model for Type 1 diabetes, prevented the autoimmune
attack and thereby the destruction of insulin-producing beta cells
in the pancreas which causes Type 1 diabetes. The DM-199 program
has now demonstrated efficacy in three critical areas of Type 1
diabetes treatment; immune therapy, beta cell therapy and glucose
control.
The research was a collaborative effort between DiaMedica and
The Sanford Project, a research initiative at Sanford Health which
has the goal to research and cure Type 1 diabetes. "We look forward
to sharing greater details of the extremely promising results of
DM-199 treatment for Type 1 diabetes at the IDF World Diabetes
Congress," stated Dr. Alexei Savinov, MD, The Sanford Project.
About The Sanford Project
The Sanford Project is one of the four initiatives made possible
through Denny Sanford's transformational gift to Sanford Health in
2007. From its inception, The Sanford Project was "designed for
results." Sanford Health will combine clinical components of
patient care and science into one of the most promising and
fast-moving fields of research; regenerative medicine. Their goal
is to research and cure Type 1 diabetes, all in pursuit of a
healthy future for our children. For further information please
visit www.sanfordproject.org.
About DiaMedica
DiaMedica is a biopharmaceutical company that has developed
novel therapeutic compounds aimed to improve the lives of patients
with diabetes and other major, medically-unmet diseases.
DiaMedica's lead compound, DM-199, represents a novel approach to
treating Type 1 and Type 2 diabetes by demonstrating significant
results against three major aspects of these diseases: 1) halting
the autoimmune attack on beta cells; 2) proliferating insulin
producing beta cells and 3) improving glucose control.
DiaMedica is also developing DM-204, a monoclonal antibody that
inhibits the enzyme glycogen synthase kinase 3 beta (GSK3B). In
pre-clinical studies, DM-204 significantly improved glucose control
and decreased blood pressure.
The company is listed on the TSX Venture Exchange under the
trading symbol 'DMA'.
Caution Regarding Forward-Looking Information
The statements made in this press release that are not
historical facts contain forward-looking information that involves
risk and uncertainties. All statements, other than statements of
historical facts, which address DiaMedica's expectations, should be
considered forward-looking statements. Such statements are based on
management's exercise of business judgment as well as assumptions
made by and information currently available to management. When
used in this document, the words "may", "will", "anticipate",
"believe", "estimate", "expect", "intend" and words of similar
import, are intended to identify any forward-looking statements.
You should not place undue reliance on these forward-looking
statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as
contained in the Company's filings with Canadian securities
regulatory authorities. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Company
undertakes no obligation, and does not intend, to update, revise or
otherwise publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date
hereof, or to reflect the occurrence of any unanticipated events.
Although management believes that expectations are based on
reasonable assumptions, no assurance can be given that these
expectations will materialize.
Contacts: DiaMedica Inc. Rick Pauls President & CEO
204.477.7590 204.453.3745 (FAX) rpauls@diamedica.com
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024